Compare Inovio Pharmaceuticals Inc (INO) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Yum! Brands, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Yum! Brands, Inc. trades at $147.13 (market cap $40.62B). The key difference: Yum! Brands, Inc. is far larger — about 455× Inovio Pharmaceuticals Inc's market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | YUM | |
|---|---|---|
Market Cap | $89.27M | $40.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $168.16 |
52-Week Low | $1.05 | $138.21 |
Enterprise Value | $60.28M | $51.88B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
YUM trades at $147.44, down 0.32% amid bearish technical signals and negative news flow from a Taco Bell lettuce contamination outbreak. Fundamentally, the company shows revenue growth to $8.21B in 2025 with strong net income margins of 20.48%, though valuation ratios like P/E of 23.86 appear elevated. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing estimates.
The stock faces near-term headwinds from the food safety crisis but maintains analyst support with a $177 consensus target representing 20% upside. Long-term growth prospects remain intact with digital expansion and brand strength, though high debt levels and competitive pressures present ongoing risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
